AFFILIATIONS
1 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
2 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
3 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
4 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
5 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
6 Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
7 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
8 AstraZeneca, Gaithersburg, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
11 Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
12 Columbia Stem Cell Initiative, New York, New York, United States, Division of Hematology/Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
ABSTRACT
BACKGROUND: The combination of 6-thioguanine (6TG) and decitabine (DEC) demonstrates clinical activity in relapsed/refractory (R/R) acute myeloid leukemia (AML), including in patients previously exposed to hypomethylating agents (HMAs), suggesting that this regimen may overcome conventional HMA resistance. Despite encouraging clinical responses, the molecular basis of sensitivity and resistance to 6TG/DEC remains poorly understood. We applied an integrated multiomic framework combining methylome-aware Oxford Nanopore long-read sequencing, RNA sequencing, and single-cell proteomics to define biological programs associated with response and resistance to 6TG/DEC therapy.
METHODS: Longitudinal bone marrow samples were collected at baseline and serial on-treatment timepoints from patients receiving 6TG/DEC and classified as complete responders (CR) or nonresponders (NR). Paired baseline and on-treatment Oxford Nanopore sequencing characterized 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), and differentially methylated regions (DMRs) in CR (n=3) and NR (n=5). Bulk RNA-seq was performed on pretreatment samples. Single-cell spatial proteomic profiling using the Pixelgen Proximity Network Assay was performed in CR (n=4) and NR (n=11) patients across serial treatment timepoints to assess cellular consequences of epigenetic remodeling.
RESULTS: Clinical responses to 6TG/DEC occurred despite prior HMA exposure, indicating that therapeutic benefit was not restricted to HMA-naïve disease. Long-read methylome profiling demonstrated that response was associated with dynamic remodeling of distal regulatory elements rather than global methylation changes. Baseline global 5mC and 5hmC levels were similar between responders and nonresponders; however, response-associated differences localized predominantly to enhancer regions.
Following treatment, responders underwent balanced bidirectional enhancer remodeling, whereas nonresponders demonstrated net enhancer hypomethylation without coordinated regulatory reorganization. Response-associated enhancer DMRs were enriched for hematopoietic and lineage-regulatory transcription factor motifs, including NF-E2, NFE2L2, and PU.1, suggesting restoration of normal hematopoietic regulatory circuitry during effective therapy. Pretreatment RNA-seq demonstrated substantial overlap between responders and nonresponders, indicating that baseline transcriptional programs alone did not explain treatment outcome. Instead, response was defined by the capacity to undergo dynamic enhancer reprogramming during therapy.
To assess the cellular consequences of these epigenetic state transitions, we performed single-cell spatial proteomic profiling. Responders demonstrated reduction of leukemic blast populations, recovery of multilineage hematopoiesis, and expansion of cytotoxic lymphoid compartments, whereas resistant AML retained leukemia-associated cellular programs and failed to undergo comparable reorganization. Similar patterns were observed in an independent cohort of HMA-resistant AML, supporting the reproducibility of these findings.
CONCLUSIONS: Response to 6TG/DEC therapy is characterized by enhancer renormalization at lineage-regulatory elements rather than global DNA hypomethylation. Responding leukemias undergo coordinated epigenetic state transitions associated with restoration of hematopoietic regulatory programs, whereas resistant AML fails to execute this renormalization despite treatment-associated methylation changes. These findings provide a mechanistic framework for the activity of 6TG/DEC in heavily pretreated AML and identify enhancer reprogramming as a central determinant of therapeutic response.